US 11,891,429 B2
Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
Bradley G. Thompson, Calgary (CA)
Assigned to Cellastra Inc., San Francisco, CA (US)
Filed by Cellastra Inc., San Francisco, CA (US)
Filed on May 14, 2021, as Appl. No. 17/320,661.
Application 17/320,661 is a continuation of application No. 16/037,769, filed on Jul. 17, 2018, abandoned.
Prior Publication US 2021/0269508 A1, Sep. 2, 2021
Int. Cl. C12N 15/79 (2006.01); C07H 21/04 (2006.01); C07K 14/79 (2006.01); A61K 31/198 (2006.01); A61P 17/02 (2006.01); A61K 48/00 (2006.01); C12N 15/69 (2006.01); A61K 38/40 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/79 (2013.01) [A61K 31/198 (2013.01); A61K 48/0058 (2013.01); A61K 48/0066 (2013.01); A61P 17/02 (2018.01); C12N 15/69 (2013.01); A61K 38/40 (2013.01); C07H 21/04 (2013.01); C12N 15/86 (2013.01)] 14 Claims
 
1. A recombinant virus vector (RVV), the RVV comprising:
a) a nucleotide sequence encoding a human lactoferrin protein or a sub-peptide thereof linked to an immunoglobulin;
b) an inverted terminal repeat; and
c) a nucleotide sequence encoding a human growth hormone (HGH) signal peptide.